In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Curis, Elan establish JV to develop hedgehog agonists; ended

Executive Summary

Along with Elan, Curis (regenerative medicine) has formed a joint venture they are calling Curis Newco, which will research and develop molecules that stimulate the hedgehog (Hh) signaling pathway, shown in previous studies to play a role in the development of the central and peripheral nervous systems.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
Deal Status
  • Concluded
Deal Type
  • Alliance
    • Includes Contract
    • Joint Venture

Related Companies